Skip to main content

Table 3 SRS Response rate at follow-up MRI

From: Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Treatment Scan interval, d (range) CR PR Stable PD
SRS + pembro
(n = 23)
57 (39-118) 8 (35%) 8 (35%) 6 (26%) 1 (4%)
SRS + ipi
(n = 31)
53 (41-95) 4 (13%) 6 (19%) 19 (61%) 2 (6%)
SRS
(n = 27)
51 (28-130) 1 (4%) 5 (19%) 18 (67%) 3 (11%)
  1. Response assessment adapted from RANO proposal (Lin et al. 2015)
  2. CR = complete response (disappearance of target lesion)
  3. PR = partial response (lesion visible, ≥ 30% decrease in max diameter)
  4. Stable = stable response (lesion visible, < 30% decrease OR <20% increase in max diameter)
  5. PD = progressive disease (lesion visible, ≥ 20% increase in max diameter)